41.24
1.05%
+0.41
Amphastar Pharmaceuticals Inc stock is currently priced at $41.24, with a 24-hour trading volume of 185.59K.
It has seen a +1.05% increased in the last 24 hours and a -4.52% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $40.76 pivot point. If it approaches the $41.44 resistance level, significant changes may occur.
Previous Close:
$40.83
Open:
$40.77
24h Volume:
185.59K
Market Cap:
$2.01B
Revenue:
$644.40M
Net Income/Loss:
$137.55M
P/E Ratio:
21.15
EPS:
1.95
Net Cash Flow:
$145.34M
1W Performance:
+3.12%
1M Performance:
-4.52%
6M Performance:
-8.19%
1Y Performance:
+8.12%
Amphastar Pharmaceuticals Inc Stock (AMPH) Company Profile
Name
Amphastar Pharmaceuticals Inc
Sector
Phone
909-980-9484
Address
11570 6th Street, Rancho Cucamonga, CA
Amphastar Pharmaceuticals Inc Stock (AMPH) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-17-23 | Initiated | BofA Securities | Neutral |
Jul-25-23 | Resumed | Jefferies | Buy |
Oct-21-22 | Resumed | Jefferies | Buy |
Jul-29-22 | Initiated | CapitalOne | Overweight |
Jan-07-22 | Upgrade | Piper Sandler | Neutral → Overweight |
Jan-08-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Oct-05-20 | Upgrade | Northland Capital | Market Perform → Outperform |
May-01-20 | Initiated | Northland Capital | Outperform |
Mar-13-19 | Downgrade | Needham | Buy → Hold |
Mar-13-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
Aug-10-18 | Reiterated | Needham | Buy |
Mar-13-18 | Reiterated | Needham | Buy |
Dec-01-17 | Reiterated | Needham | Buy |
Nov-09-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
Sep-27-17 | Reiterated | Needham | Buy |
Mar-14-17 | Downgrade | Raymond James | Strong Buy → Outperform |
Aug-09-16 | Reiterated | Needham | Buy |
May-10-16 | Reiterated | Needham | Buy |
Feb-19-16 | Initiated | Wells Fargo | Outperform |
Jun-19-15 | Reiterated | Needham | Buy |
Jun-03-15 | Initiated | Raymond James | Strong Buy |
Jul-21-14 | Initiated | Needham | Buy |
View All
Amphastar Pharmaceuticals Inc Stock (AMPH) Latest News
New Strong Sell Stocks for April 26th
Zacks Investment Research
Amphastar Pharmaceuticals Interested In Potential Acquisitions In Endocrinology-Focused Companies
Benzinga
Amphastar Pharmaceuticals (AMPH) Stock Moves -1%: What You Should Know
Zacks Investment Research
Is Amphastar (AMPH) a Buy as Wall Street Analysts Look Optimistic?
Zacks Investment Research
Amphastar Pharmaceuticals (AMPH) Registers a Bigger Fall Than the Market: Important Facts to Note
Zacks Investment Research
Amphastar Pharmaceuticals (AMPH) Stock Sinks As Market Gains: What You Should Know
Zacks Investment Research
Amphastar Pharmaceuticals Inc Stock (AMPH) Financials Data
Amphastar Pharmaceuticals Inc (AMPH) Revenue 2024
AMPH reported a revenue (TTM) of $644.39 million for the quarter ending December 31, 2023, a +29.14% rise year-over-year.
Amphastar Pharmaceuticals Inc (AMPH) Net Income 2024
AMPH net income (TTM) was $137.54 million for the quarter ending December 31, 2023, a +50.51% increase year-over-year.
Amphastar Pharmaceuticals Inc (AMPH) Cash Flow 2024
AMPH recorded a free cash flow (TTM) of $145.34 million for the quarter ending December 31, 2023, a +123.09% increase year-over-year.
Amphastar Pharmaceuticals Inc (AMPH) Earnings per Share 2024
AMPH earnings per share (TTM) was $2.58 for the quarter ending December 31, 2023, a +46.59% growth year-over-year.
Amphastar Pharmaceuticals Inc Stock (AMPH) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Zhang Jack Y. | CEO & Chief Scientific Officer |
Mar 15 '24 |
Option Exercise |
12.46 |
722,046 |
8,996,693 |
2,858,043 |
Zhang Jack Y. | CEO & Chief Scientific Officer |
Mar 15 '24 |
Option Exercise |
12.46 |
310,930 |
3,874,188 |
1,439,466 |
PETERS WILLIAM J | CFO, EVP & TREASURER |
Mar 06 '24 |
Option Exercise |
11.33 |
8,826 |
99,999 |
129,626 |
PETERS WILLIAM J | CFO, EVP & TREASURER |
Mar 06 '24 |
Sale |
46.48 |
18,136 |
842,883 |
111,490 |
ZASLOFF MICHAEL A | Director |
Mar 05 '24 |
Sale |
47.18 |
12,500 |
589,724 |
21,326 |
Petersen Floyd F. | Director |
Mar 01 '24 |
Sale |
45.69 |
500 |
22,847 |
79,833 |
Petersen Floyd F. | Director |
Feb 01 '24 |
Sale |
53.10 |
500 |
26,548 |
80,333 |
Luo Mary Z. | COO,Chief Scientist & Chairman |
Jan 10 '24 |
Sale |
54.59 |
131,386 |
7,171,768 |
1,104,416 |
Luo Mary Z. | COO,Chief Scientist & Chairman |
Jan 09 '24 |
Sale |
57.14 |
86,156 |
4,923,232 |
1,235,802 |
Luo Mary Z. | COO,Chief Scientist & Chairman |
Jan 08 '24 |
Sale |
58.93 |
133,644 |
7,875,476 |
1,321,958 |
About Amphastar Pharmaceuticals Inc
Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients. The company offers enoxaparin, a low molecular weight heparin that is used as an anticoagulant for the prevention and treatment of deep vein thrombosis; naloxone for opioid overdose; Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; and lidocaine jelly, a local anesthetic product for urological procedures. It also provides lidocaine topical solution for various procedures; phytonadione injection for newborn babies; syringe products, such as morphine, atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate for emergency use in hospital settings; lorazepam injection for surgery and medical procedures; ketorolac for acute pain management; procainamide for documented ventricular arrhythmias; medroxyprogesterone acetate injectable suspension for the prevention of pregnancy. In addition, the company manufactures and distributes recombinant human and porcine insulins. Further, it develops Primatene Mist, an over-the-counter epinephrine inhalation product candidate for the temporary relief of mild symptoms of intermittent asthma. Additionally, the company has a pipeline of 20 generic and proprietary product candidates in various stages of development for various indications. Its products are used in hospital or urgent care clinical settings, and primarily contracted and distributed through group purchasing organizations and drug wholesalers. Amphastar Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Cap:
|
Volume (24h):